|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
Valuation Estimation |
EPS (Current/Estimated)
-3.69/-5.35
|
Enterprise Value
3.26B
|
Balance Sheet |
Book Value Per Share
14.24
|
Cash Flow |
Cash Flow Yield
--
|
Income Statement |
Total Revenue
1.04M
|
Operating Revenue Per Share
0.05
|
Industry Comparison
|
||||||||||||||||||||||||||||||||||||||||||||||||
|

Industry overview quotes are at least 15 minutes delayed
Business Description
|
|||
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant. |